<DOC>
	<DOCNO>NCT00003929</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Radiation therapy use high-energy x-rays damage cancer cell . Combining chemotherapy radiation therapy may kill cancer cell . Colony-stimulating factor filgrastim allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase II trial study effectiveness lomustine , procarbazine , filgrastim , radiation therapy treat patient primary central nervous system lymphoma .</brief_summary>
	<brief_title>Chemotherapy , Filgrastim , Radiation Therapy Treating Patients With Primary Central Nervous System Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , response duration , survival patient AIDS-related immunocompetent primary central nervous system lymphoma treatment oral lomustine procarbazine , filgrastim ( G-CSF ) , radiotherapy . II . Determine toxicity combine modality patient . III . Determine quality life patient . OUTLINE : Patients stratify CD4 count ( 50/mm3 v great 50/mm3 ) . Patients receive oral lomustine day 1 oral procarbazine day 1-10 day 22-31 . Filgrastim ( G-CSF ) administer subcutaneously daily day 12-21 day 33-42 , absolute neutrophil count recover . Patients complete response 6 week receive one additional course chemotherapy prior radiotherapy . Patients partial response , stable disease , disease progression 6 week proceed radiotherapy without receive second course chemotherapy . Whole brain radiotherapy administer daily 28 day begin 1-3 week follow chemotherapy . Quality life assess prior therapy , 3 6 week , every 2 month follow radiotherapy . Patients follow every 2 month death . PROJECTED ACCRUAL : Approximately 16 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven AIDSrelated nonHodgkin 's lymphoma CNS non AIDSrelated , nonHodgkin 's lymphoma CNS also eligible , eligible high priority clinical trial PATIENT CHARACTERISTICS : Age : 0120 Performance status : ECOG 02 Life expectancy : At least 6 week Hematopoietic : WBC least 1500/ mm3 Platelets least 50,000/mm3 Hepatic : Serum bilirubin great 3.0 mg/dL Renal : Serum creatinine great 3.0 mg/dL Cardiovascular : Pulmonary : Other : Active infection ( ) allow drug receive treatment No Zidovudine combine modality chemotherapy radition Negative CSF cytology PRIOR CONCURRENT THERAPY : Biologic therapy : Chemotherapy : No prior chemotherapy Endocrine therapy : Steroids may use concurrently . Doses low possible . Increases steroid study 's upper limit result patient go study . Radiotherapy : No prior radiotherapy Surgery : Prior surgical debulking allow</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>primary central nervous system lymphoma</keyword>
	<keyword>AIDS-related primary CNS lymphoma</keyword>
</DOC>